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Introduction {#sec001}
============

The *Dendrobium* plants are vastly distributed in a large area including tropical and subtropical regions of Asia and North Australia \[[@pone.0238509.ref001]\]. Because of the extensive geographical distribution, *Dendrobium* becomes one of the largest genera in *Orchidaceae*, composing of approximately 1500--2000 species \[[@pone.0238509.ref002]\]. Of these, about 41 species have been used in traditional Chinese medicine \[[@pone.0238509.ref003]\]. Various groups of secondary metabolites have been reported, for instance, alkaloids, coumarins, bibenzyls, fluorenones, phenanthrenes, and sesquiterpenoids. Some of these metabolites exhibit a wide spectrum of pharmacological activities, including antioxidant, anti-inflammatory, antidiabetic, antitumor, antimicrobial and neuroprotective activities \[[@pone.0238509.ref002], [@pone.0238509.ref004]\]. For example, purified bibenzyls and phenanthrenes, such as chrysotoxine from *D*. *pulchellum*, cypripedin from *D*. *densiflorum*, gigantol from *D*. *draconis* and moscatilin from *D*. *brymerianum*, have been demonstrated to show promising inhibitory effects on human *in vitro* cell line models of lung cancer growth and metastasis \[[@pone.0238509.ref005]--[@pone.0238509.ref009]\]. However, whether these therapeutic effects can be also seen in primary human cells and/or *in vivo* remains to be investigated. Nevertheless, it is also unclear whether systemic administration of these compounds would influence phenotypes and/or functions of other cell types such as circulating immune cells in the peripheral blood.

The lung is a highly specialized organ that is continuously exposed to numerous pathogens, pollutants, oxidants, gases, and toxicants from the outside ambient air, which makes it susceptible to varying degrees of oxidative and inflammatory injury. Under some circumstances, inflammatory responses can result in the release of proinflammatory cytokines and chemokines, which in turn stimulate the influx of polymorphonuclear leukocytes (PMNs) and monocytes into the lung to combat the invading pathogens. However, chronic inflammation-induced cytokine production of monocytes in the lung may predispose individuals to lung cancer \[[@pone.0238509.ref010]\]. Tumor-infiltrating myeloid cells (TIMs), comprising monocytes, macrophages, dendritic cells and neutrophils, have emerged as key regulators of cancer growth and recurrence \[[@pone.0238509.ref011], [@pone.0238509.ref012]\]. The infiltration of monocytes into human specimens of non-small-cell lung cancer was found to be increased compared with normal lung tissue \[[@pone.0238509.ref012]\]. Although, it remains elusive, which monocyte sub-populations recruit into tumors, these infiltrating cells showed increased expression of chemokines and chemotactic activity in tumor environment \[[@pone.0238509.ref011]\]. Increased numbers and inflammatory activity of tumor-associated, monocyte-derived macrophages were linked to poor prognosis in lung cancer patients \[[@pone.0238509.ref012], [@pone.0238509.ref013]\]. Amelioration of monocyte-induced inflammation and/or infiltration may synergize to inhibit tumor growth and metastasis, and lead to a better prognosis of patients with lung cancer.

Furthermore, monocytes are crucial for the efficiency of the immune system, since they act in numerous immunological mechanisms, such as replenishment of resident macrophages, production of dendritic cell subsets, and acute and chronic inflammatory responses \[[@pone.0238509.ref014],[@pone.0238509.ref015]\]. The cellular activity of these cells involves the production of several molecules responsible for killing of pathogens (H~2~O~2~, NO), cellular recruitment (IL-8, CCL2, and CCL3), pro-inflammatory activation (TNF, IL-1β, and IL-6), polarization of adaptive immune response (IL-12), regulation of inflammation (IL-10 and TGF-β1), and tissue repair (TGF-β1 and bFGF) \[[@pone.0238509.ref016]\]. Monocyte dysregulation, which is generally indicated by intense production of inflammatory mediators, has been observed in several inflammatory diseases, including sepsis \[[@pone.0238509.ref017]\], atherosclerosis \[[@pone.0238509.ref018]\], rheumatoid arthritis (RA) \[[@pone.0238509.ref019]\], and hepatic fibrosis \[[@pone.0238509.ref020]\]. High levels of TNF and IL-6 are associated with worse prognoses in septicemia \[[@pone.0238509.ref021]\] and progression and worsening of RA \[[@pone.0238509.ref022]\].

In this study, we aimed to investigate the immune modulatory activities on circulating monocytes of four known *Dendrobium* substances, which have already been shown to exert therapeutic effects in *in vitro* models of lung cancer \[[@pone.0238509.ref005]--[@pone.0238509.ref009]\], as well as one newly identified bibenzyl *Dendrobium* compound. All five compounds were isolated, purified and identified from *Dendrobium lindleyi* Steud, known in Thai as "Ueang Pueng" \[[@pone.0238509.ref023]\]. This orchid is widely distributed in India (Sikkim), China (Guangdong, Hainan, Guangxi, and Guizhou), Hongkong, Bhutan and Southeast Asia (Thailand, Myanmar, Laos, and Vietnam) \[[@pone.0238509.ref003]\]. To our knowledge, chemical constituents and biological activities of compounds isolated from this orchid have never been investigated before. To assess their immune modulatory activities on circulating monocytes of the peripheral blood, we established an *ex vivo* model of primary human monocytes with low cell attachment, in which we attempted to minimize differentiation of monocyte into macrophage *ex vivo*. Our results revealed increased frequencies of TNF- and IL-6-expressing monocytes after treatment with gigantol and cypripedin, whereas chrysotoxine and moscatilin did not alter the expression of these cytokines in monocytes. Interestingly, the new 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl derivative alleviated lipopolysaccharide (LPS)-induced cytokine production of primary human monocytes, suggesting immune modulatory activity.

Materials and methods {#sec002}
=====================

Plant material {#sec003}
--------------

The whole plant of *D*. *lindleyi* was purchased in September 2009 from Chatuchak market, Bangkok, Thailand (13°47\'57.1\"N, 100°32\'55.2\"E). Plant identification was done by one of the authors (B. Sritularak). A voucher specimen (BS-DL-092552) has been deposited at the Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University.

Extraction and isolation {#sec004}
------------------------

*Dendrobium lindleyi* (1.2 kg) was extracted as previously described \[[@pone.0238509.ref026]\]. Briefly, the dried whole plant was grounded extracted with methanol (MeOH) at room temperature (RT). The extract was then evaporated under reduced pressure. The MeOH residue (97 g) was suspended in water and partitioned with immiscible organic solvents comprising EtOAc and *n*-BuOH. The EtOAc extract (34 g) was fractionated on silica gel column (EtOAc-hexane, gradient) to yield in total of 10 fractions (A-J). Fraction F (3.2 g) was separated by column chromatography over silica gel (EtOAc -hexane, gradient) to obtain 13 fractions (FI-FXIII). Fraction FVIII (140 mg) was purified on Sephadex LH-20 column (MeOH) to furnish chrysotoxine (\#**2**) (90 mg), gigantol (\#**3**) (20 mg) and cypripedin (\#**4**) (25 mg), respectively. Moscatilin (\#**5**) (90 mg) was purified from fraction FX (340 mg) on Sephadex LH-20 (MeOH). Fraction G (2.6 g) was fractionated by CC ((silica gel, EtOAc-hexane, gradient) and then by Sephadex LH-20 (MeOH) to afford \#**1** (47 mg).

Analytical procedures {#sec005}
---------------------

Bruker micro TOF mass spectrometer (ESI-MS) was used for mass spectrometric analysis and a Milton Roy Spectronic 300 Array spectrophotometer was utilized for UV spectroscopic measurement. NMR spectra were obtained on a Bruker Avance III HD 500 NMR spectrometer or a Bruker Avance DPX-300 FT-NMR spectrometer. The recording of IR spectra was done by a Perkin-Elmer FT-IR 1760X spectrophotometer. Column chromatography (CC) was conducted on different stationary phases. These were silica gel 60 (Merck, Kieselgel 60, 70--320 μm), silica gel 60 (Merck, Kieselgel 60, 230--400 μm), C-18 (Merck, Kieselgel 60 RP-18, 40--63 μm) and Sephadex LH-20 (25--100 μm, GE Healthcare).

Buffy coats and monocyte isolation {#sec006}
----------------------------------

Buffy coats from healthy individuals were obtained from the German Red Cross (GRC). Blood donors gave informed consent to perform blood collection and to use the buffy coats samples for research. The research purpose was approved by the Ethics Committee of Charité --Universitätsmedizin Berlin.

Human peripheral blood mononuclear cells (PBMCs) were isolated and aliquoted at 20 x 10^6^ PBMCs (per mL) were cryopreserved in liquid nitrogen tank until analysis. Frozen PBMCs of three biologically independent donors were thawed, washed and pooled in MACS buffer (0.5% BSA in PBS containing 2 mM EDTA). Monocytes were isolated using negative selection, pan-monocyte Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer's specifications. Briefly, PBMCs were resuspended in 120 μL of MACS buffer. Thirty micro liters of FcR blocking reagent and 30 μL of biotin-antibody cocktail were added, mixed thoroughly and incubated at 4°C. After 5 min incubation, 90 μL of MACS buffer and 60 μL of anti-biotin micro beads were added and incubated at 4°C for 10 min. Stained ells were then washed with MACS buffer and pelleted (4°C, 300 x g, 8 min). The pellet was then resuspended in 500 μL of MACS buffer and loaded onto the MACS column. The column was then washed twice with MACS buffer. The flow-through and washed fraction containing unlabeled monocytes was collected. Cell number and viability were determined by 0.2% trypan blue staining.

Cell culture and stimulation {#sec007}
----------------------------

Isolated monocytes were resuspended in 1 mL of RPMI1640 (Biochrom GmbH, Berlin, Germany) containing 10% heat-inactivated fetal calf serum (FCS) (Sigma-Aldrich, St. Louis, USA), penicillin (100 U/mL; Biochrom GmbH, Berlin, Germany) and streptomycin (100μg/mL; Biochrom GmbH, Berlin, Germany). Cell concentration was adjusted to \~ 2 x 10^6^ cells/mL. About 2 x 10^5^ cells (per well) were transferred into ultra-low-attachment 96-well plate (Corning, New York, USA). Different concentrations of compounds ([Fig 3A](#pone.0238509.g003){ref-type="fig"}) were added to the cell culture. To inhibit protein transport from Golgi apparatus to the endoplasmic reticulum, monensin (5 μg/mL; BioLegend, San Diego, USA) was also added right after the application of *Dendrobium* compounds. After two hours incubation, cells were stimulated by adding 100 ng/mL of lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis, USA). Cells were cultured for 4 more hours or overnight (18 hours). Finally, cells were analysed by flow cytometry. Control conditions were naïve cells (without treatment of *Dendrobium* compounds and LPS) and unstimulated cells that were previously treated with the *Dendrobium* compounds.

Flow cytometry {#sec008}
--------------

Monocytes were incubated for 10 min in FcR-blocking buffer (1:100; Miltenyi Biotec, Bergisch Gladbach, Germany) at 4°C, to block unspecific binding of antibodies to Fc-receptors. Next, cells were incubated with conjugated antibodies detecting extracellular epitopes (i.e. CD3-PE-Cy7 / SK7 / BioLegend; CD335-PE / 9E2 / BioLegend; CD16-APC-Cy7 / 3G8 / BioLegend; CD11c-APC / 3.9 / BioLegend; HLA-DR-pacific blue / L243 / BioLegend and CD14-FITC / RMO52 / Beckman) diluted in staining buffer (0.5% BSA in PBS containing 2 mM EDTA) for 20 min at 4°C. Cells were then washed with 1 mL of staining buffer, and further incubated in 200 μL of intracellular fixation/permeation buffer (eBioscience, California, USA) for 30 min at 4°C. After washing with 1 mL of permeation buffer (eBioscience, California, USA), 50 μL of antibody cocktail detecting intracellular proteins (i.e. TNF-brilliant violet / Mab11 / BioLegend; IL-6-PE-Cy7 / MQ2-13A5 / BioLegend; CCL2-PE / 5D3-F7 / BioLegend and CD68-PerCP-Cy5.5 / Y1/82A / BioLegend) was added and further incubated for 30 min at 4°C. Cells were then washed with staining buffer and pelleted at 300 x g, 4°C for 10 min. Stained cells were finally resuspended in staining buffer. Cell viability was determined using Propidium Iodide (25 μg/mL; Thermo Fisher Scientific, Massachusetts, USA). Protein expression was detected on a 3-laser BD FACSCanto II machine (BD Biosciences, New Jersey, USA) with software BD DIVA version 8.1. FlowJo software version 10.1 (Ashland, OR, USA) was used to determine the phenotype on the basis of fluorescence intensity.

Statistical analysis {#sec009}
--------------------

Acquired FACS data were extracted in the Flow Cytometry Standard (\*.fcs) format. Cell populations were gated in FlowJo (Becton, Dickinson and Company, New Jersey, USA). Frequency of cells positive for a given signal was extracted into GraphPad Prism 8 (GraphPad Software Inc., California, USA) and statistically analyzed by a one-way ANOVA or a multiple t-test (as indicated), with a confidence interval of 95% (α = 0.05).

Results {#sec010}
=======

Establishment of low-attachment primary human monocyte cultures for functional analysis {#sec011}
---------------------------------------------------------------------------------------

It has been demonstrated that *ex vivo* culture of human monocytes using classical polypropylene cell culture plates resulted in phenotypic and functional changes, such as an increased granularity and reduced transendothelial diapedesis function \[[@pone.0238509.ref024]\]. Therefore, we newly established an *ex vivo* culture system using an ultra-low attachment multiple well-plate ([Fig 1A](#pone.0238509.g001){ref-type="fig"}). First, we used peripheral blood mononuclear cells (PBMCs) to optimize the culture system ([Fig 1A and 1B](#pone.0238509.g001){ref-type="fig"}). We observed a better preservation of the cell composition in the culture system using RPMI-1640 medium compared with reduced serum medium OptiMEM ([Fig 1C and 1D](#pone.0238509.g001){ref-type="fig"}).

![Low-attached *in vitro* cultured model of human monocytes.\
(**A**) Schematic representation of experimental procedure. (**B**) Dot plots demonstrate flow cytometric gating strategy used to obtain monocytes (G7, G8 and G9) for all samples. (**C**) Bar graphs show cell numbers in different culture conditions at different time points *in vitro*. (**D**) Bar graphs show different cell composition of PBMCs that were cultured in OptiMEM or RPMI medium conditions at 2 and 4 hours *in vitro*. Multiple t-test, corrected for multiple comparisons using Holm-Sidak method, \**P* \< 0.05, \*\**P* \< 0.01.](pone.0238509.g001){#pone.0238509.g001}

Next, we tested the LPS-induced inflammatory responses of monocytes under these culture conditions. We isolated monocytes (both CD14^lo^ and CD14^hi^ monocytes) from PBMCs using magnetic activated cell sorting (MACS) (Figs [1A](#pone.0238509.g001){ref-type="fig"} and [2A](#pone.0238509.g002){ref-type="fig"}). Isolated monocytes were then cultured in the established low-attachment culture system in the presence of 100 ng/mL LPS or PBS (control) for 6 hours. Compared to control, the cell composition of the monocyte population was changed after LPS stimulation. Namely, a strong reduction of CD14^+^CD16^+^ monocytes and a moderately decreased frequency of CD14^hi^ monocytes were found ([Fig 2B](#pone.0238509.g002){ref-type="fig"}). As expected, increased expression of TNF was detected in all three monocyte populations after LPS stimulation, with the highest response in CD14^hi^ inflammatory monocytes ([Fig 2C and 2D](#pone.0238509.g002){ref-type="fig"}). Furthermore, we found increased expression of IL-6 in CD14^hi^ and CD14^lo^ monocytes after LPS stimulation, whereas MCP-1 (or CCL2) and CD68 were unchanged under these conditions ([Fig 2E and 2F](#pone.0238509.g002){ref-type="fig"}).

![LPS-induced cytokine production of cultured monocytes.\
(**A**) Dot plots demonstrate flow cytometric gating strategy used to obtain monocytes (G4, G5 and G6) for all samples. (**B**) Bar graphs show changes in monocyte composition after LPS stimulation, compared with naïve monocytes. Multiple t-test, corrected for multiple comparisons using Holm-Sidak method, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. (**C**) Histograms demonstrate fluorescent intensity representing LPS-induced TNF expression in different monocyte subsets, compared to naïve monocytes (unstimulated, PBS-treated). (**D**) Bar graphs show quantitative analysis of fluorescent intensity representing LPS-induced TNF expression in different monocyte subsets, compared to naïve monocytes (unstimulated, PBS-treated). Each dot represents an independent measurement. One-way ANOVA, corrected for multiple comparisons using Tukey Test, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. (**E**) Histograms demonstrate fluorescent intensity representing LPS-induced cytokine expression of CD14^hi^ monocytes (red line), compared to naïve CD14^hi^ monocytes (unstimulated, PBS-treated; dashed line). (**F**) Bar graphs show quantitative analysis of fluorescent intensity representing LPS-induced cytokine expression in different monocyte subsets, compared to naïve monocytes (unstimulated, PBS-treated). One-way ANOVA, corrected for multiple comparisons using Tukey Test, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001.](pone.0238509.g002){#pone.0238509.g002}

*Dendrobium* compound isolation, purification and identification {#sec012}
----------------------------------------------------------------

Phytochemical investigation from the whole plant of *Dendrobium lindleyi* ([Fig 3A](#pone.0238509.g003){ref-type="fig"}) revealed the isolation of a novel bibenzyl ([Fig 3A](#pone.0238509.g003){ref-type="fig"}, **\#1**), along with four known compounds, which include chrysotoxine ([Fig 3A](#pone.0238509.g003){ref-type="fig"}, **\#2**) \[[@pone.0238509.ref005], [@pone.0238509.ref006]\], gigantol ([Fig 3A](#pone.0238509.g003){ref-type="fig"}, **\#3**) \[[@pone.0238509.ref008], [@pone.0238509.ref025]--[@pone.0238509.ref028]\], cypripedin ([Fig 3A](#pone.0238509.g003){ref-type="fig"}, **\#4**) \[[@pone.0238509.ref007],[@pone.0238509.ref029],[@pone.0238509.ref030]\] and moscatilin ([Fig 3A](#pone.0238509.g003){ref-type="fig"}, **\#5**) \[[@pone.0238509.ref009],[@pone.0238509.ref027],[@pone.0238509.ref031],[@pone.0238509.ref032]\]. The structure of a new compound was elucidated through analysis of its spectroscopic data.

![Isolated compounds from *Dendrobium lindleyi*.\
(**A**) Chemical structures of five compounds isolated and purified from *Dendrobium lindleyi*. (**B**) Chemical structure characterization of 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl using ^1^H NMR and ^13^C NMR.](pone.0238509.g003){#pone.0238509.g003}

Compound **\#1** was obtained as a brown amorphous solid; UV (MeOH) λ~max~ (log ε) 220 (4.09), 229 (4.08), 285 (3.76) nm; IR (film) ν~max~: 3428, 2924, 1724, 1629, 1605, 1515, 1453, 1263, 1093, 1027 cm^-1^; ^1^H NMR (500 MHz, CDCl~3~) and ^13^C NMR (125 MHz, CDCl~3~) spectral data, see [Fig 3B](#pone.0238509.g003){ref-type="fig"}; HR-ESI-MS: *m/z* 327.1212 \[M+Na\]^+^ (calcd. for C~17~H~20~O~5~Na, 327.1208). The positive HR-ESI-MS showed an \[M+Na\]^+^ ion at *m/z* 327.1212 (calcd. for C~17~H~20~O~5~Na, 327.1208), suggesting the molecular formula C~17~H~20~O~5~. The absorption bands of the IR spectrum were defined as hydroxyl (3428 cm^-1^), aromatic ring (2924, 1605 cm^-1^) and methylene (1453 cm^-1^) groups. The UV absorptions at 220, 229 and 285 nm were indicative of a bibenzyl nucleus \[[@pone.0238509.ref033]\]. This was confirmed by the presence of two pairs of methylene protons at δ 2.81 (H~2~-α) and 2.84 (H~2~-α′) ppm, which correlated to the carbon atoms at δ 38.0 (C-α) and 37.6 (C-α′) ppm, respectively. The ^1^H NMR spectrum ([Fig 3B](#pone.0238509.g003){ref-type="fig"}) also displayed five aromatic protons at δ 6.26--6.81 ppm and three methoxyl groups at δ 3.85 (3H, s, MeO-3), 3.87 (3H, s, MeO-3′) and 3.88 (3H, s, MeO-4′). On ring A, the ^1^H NMR spectrum showed signals for two doublets at δ 6.26 (*J* = 2.0 Hz, H-2) and 6.48 (*J* = 2.0 Hz, H-6), which correlated to C-α in the HMBC spectrum. The first methoxyl group (δ 3.85) was located at C-3 based on its NOESY correlation with H-2. The ^1^H NMR ABM coupling system of ring B appeared at δ 6.69 (1H, d, *J* = 2.0 Hz, H-2′), 6.73 (1H, dd, *J* = 8.0, 2.0 Hz, H-6′) and 6.81 (1H, d, *J* = 8.0 Hz, H-5′). The HMBC correlations of C-α′ with H-2′ and H-6′ and the NOESY cross-peak of two methoxy groups at δ 3.87 and δ 3.88 with H-2′ and H-5′, respectively, placed the second methoxyl group at C-3′ (δ 148.7) and the third methoxyl group at C-4′ (δ 147.2). Based on above spectral data, compound **\#1** was identified as 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl.

Evaluation of immune modulatory effects of *Dendrobium* compounds {#sec013}
-----------------------------------------------------------------

To assess immune modulatory effects of all five *Dendrobium* compounds, we cultured MACS-isolated primary human monocytes under our established culture conditions (Figs [1](#pone.0238509.g001){ref-type="fig"} and [2](#pone.0238509.g002){ref-type="fig"}), including an inhibitor of intracellular protein transport--monensin, in the presence of *Dendrobium* compounds, which were 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl (**\#1**), chrysotoxine (**\#2**), gigantol (**\#3**), cypripedin (**\#4**) and moscatilin (**\#5**). Since these five compounds were diluted in dimethyl sulfoxide (DMSO), the same concentration of DMSO was added to the control culture without any compounds. We tested three known therapeutic concentrations \[[@pone.0238509.ref005]--[@pone.0238509.ref009]\], which were 5, 10 and 20 μM. After 2 hours of incubation, we stimulated monocytes by adding 100 ng/mL LPS and incubated for four more hours. We observed an increased frequency of TNF-expressing cells in gigantol (**\#3**)- and cypripedin (**\#4**)-treated monocytes without LPS stimulation, suggesting immune modulatory effects of these compounds on monocyte responses *ex vivo* ([Fig 4A and 4B](#pone.0238509.g004){ref-type="fig"}). After LPS stimulation, we detected increased frequencies of TNF- and IL-6-expressing monocytes, which were most pronounced in CD14^hi^ inflammatory monocytes ([Fig 4A and 4B](#pone.0238509.g004){ref-type="fig"}), which is in line with the results shown in [Fig 2](#pone.0238509.g002){ref-type="fig"}. Although we observed decreased frequencies of LPS-induced TNF- and IL-6-expressing cells in monocytes treated with 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl (**\#1**), chrysotoxine (**\#2**) and moscatilin (**\#5**), only the compound **\#1** showed promising dose-dependent positive effects ([Fig 4A--4D](#pone.0238509.g004){ref-type="fig"}). Therefore, we selected the compound **\#1** for a further evaluation. We tested whether the immune modulatory effects of *Dendrobium* compounds on monocytes persisted also after long-term exposure to LPS. To do so, the isolated monocytes were first incubated in the presence of the compound **\#1** for two hours followed by overnight LPS-stimulation in a presence of monensin (5 μg/mL). We observed decreased expression of CD14 of the overnight cultured monocytes, and an increased abundance of TNF- and IL-6-expressing CD11c^lo^ monocytes ([Fig 5A](#pone.0238509.g005){ref-type="fig"}), especially in the CD14^hi^HLA-DR^+^ sub-population. Overnight exposure of monocytes to compound **\#1** resulted in changes in the monocyte composition, indicating as an increased abundance of CD14^lo^HLA-DR^-^ and CD14^lo^HLA-DR^+^ cells and a decreased abundance of CD14^hi^HLA-DR^+^ cells ([Fig 5B](#pone.0238509.g005){ref-type="fig"}). These changes were found at a highest degree in monocytes treated with 20 μM of **\#1**. Furthermore, these observed changes were more pronounced in LPS-stimulated monocytes ([Fig 5B](#pone.0238509.g005){ref-type="fig"}, +LPS). Similar to the short-term incubation ([Fig 4](#pone.0238509.g004){ref-type="fig"}), CD14^hi^ monocytes were the main source of TNF- and IL-6-expressing cells ([Fig 5A, 5C & 5D](#pone.0238509.g005){ref-type="fig"}). Overnight incubation with 20 μM of the compound **\#1** alone induced TNF expression in CD14^lo^HLA-DR^+^ and CD14^lo^HLA-DR^-^ cells ([Fig 5C](#pone.0238509.g005){ref-type="fig"}), while under LPS-stimulation it was downmodulating the LPS-induced TNF-expression ([Fig 5C](#pone.0238509.g005){ref-type="fig"}). In comparison to the control cells (without the compound **\#1**), a treatment with 10 μM of **\#1** could decreased LPS-induced TNF expression in all monocyte subsets ([Fig 5C](#pone.0238509.g005){ref-type="fig"}). The treatments with either 5 or 20 μM of **\#1** could only decreased the LPS-induced TNF expression in CD14^hi^HLA-DR^+^ monocytes ([Fig 5C](#pone.0238509.g005){ref-type="fig"}). Without LPS-stimulation, the compound **\#1** induced IL-6 expression in both CD14^lo^ and CD14^hi^HLA-DR^+^ monocytes, but not in CD14^lo^HLA-DR^-^ cells ([Fig 5D](#pone.0238509.g005){ref-type="fig"}). Interestingly, the 5 and 10 μM of the compound **\#1** strongly induced IL-6 expression in all monocyte subsets under LPS stimulation conditions, whereas the 20 μM concentration did not affect the expression of IL-6 in all three subsets ([Fig 5D](#pone.0238509.g005){ref-type="fig"}). The findings demonstrate a dose-dependent activating and/or immune modulatory effects of the compound **\#1**, which are observed to be different in different monocyte sub-populations.

![Immune modulatory effect of isolated compounds from *Dendrobium lindleyi* on LPS-stimulated human monocytes.\
Immune modulatory effect of all five *Dendrobium* compounds on LPS-induced TNF (**A,C**) and IL-6 (**B,D**) expression of monocytes *in vitro* were evaluated. (**A-B**) Bar graphs show the mean frequency (%) of CD14^lo^ and CD14^hi^ monocytes, which express TNF and IL-6, compared to naïve monocytes (no LPS). This is an explorative screening experiment, in which each condition (or each concentration) was analyzed in duplicate, thus no variation was shown. (**C-D**) The X-Y graphs show the correlation between the frequency (%) of TNF- or IL-6-expressing CD14^hi^ or CD14^lo^ monocytes and the concentration of all five *Dendrobium* compounds (\#1 - \#5).](pone.0238509.g004){#pone.0238509.g004}

![Immune modulatory effect of 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl on long-term LPS-stimulation of human monocytes.\
(**A**) Contour plots demonstrate flow cytometric gating strategy used to analyze the long-term culture of low-attached monocytes for all samples. Expression of TNF and IL-6 of three monocyte subsets (G1, G2 and G3) were shown. (**B**) Bar graphs show changes in monocyte composition after overnight incubation with 5, 10 or 20 μM of 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl with (+ LPS) or without LPS (no LPS) stimulation. (**C**) Bar graphs show the mean frequency (%) of TNF-expressing monocytes after overnight incubation with 5, 10 or 20 μM of 4,5-dihydroxy-3,3',4'-trimethoxybibenzyl with (+ LPS) or without LPS (no LPS) stimulation. (**D**) Bar graphs show the mean frequency (%) of IL-6-expressing monocytes after overnight incubation with 5, 10 or 20 μM of 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl with (+ LPS) or without LPS (no LPS) stimulation. One-way ANOVA, corrected for multiple comparisons using Tukey Test, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001.](pone.0238509.g005){#pone.0238509.g005}

Discussion {#sec014}
==========

In this study, we demonstrated the use of low-attached culture model of primary human monocytes as a tool to study immune modulatory effects of purified natural products (the *Dendrobium* compounds). We showed the immune modulatory potential of a novel *Dendrobium* compound: 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl, which appeared to be dose-dependent and different between monocyte subsets. In addition, we have tested those known compounds including chrysotoxine (**\#2**), gigantol (**\#3**), cypripedin (**\#4**) and moscatilin (**\#5**), which were proposed as potential candidates for the development of cancer therapy. However, these compounds appeared to have either less immune modulatory activity or even more inflammatory effect on primary monocytes, compared with the compound **\#1**. Our findings suggest an importance and/or feasibility of using *ex vivo* studied models of different primary human (immune) cells to estimate the therapeutic potential and/or any potential adverse effects of purified natural products, which will further facilitate the adjustment of developmental potential of each isolated compound in diseases.

In the low-attached monocyte culture model used in this study, we found stronger responses to TLR4 agonist LPS of CD14^hi^ monocytes, compared to CD14^lo^ monocytes, on the basis of the expression of inflammatory cytokines especially TNF and IL-6. Our results are in line with the study by Cros *et al*. in which CD14^dim^ was demonstrated to respond poorly to agonists of TLR1, TLR2 and TLR4 \[[@pone.0238509.ref034]\]. The inflammatory cytokine TNF has been shown to be involved in many biological processes including fever, apoptosis, and infection-induced cachexia \[[@pone.0238509.ref016]\], as well as in inflammation-associated diseases, for example rheumatoid arthritis \[[@pone.0238509.ref035]\], acquired generalized lipodystrophy and combined Crohn's disease \[[@pone.0238509.ref036]\], Crohn\'s disease \[[@pone.0238509.ref037]\], and type 2 diabetes \[[@pone.0238509.ref038]\]. Moreover, chemokine such as TNF can also induce activate inflammatory responses, and are implicated in the regulation of tumor development and growth via regulation of tumor-associated angiogenesis, by activation of host immunological responses or by direct inhibition of tumor cell proliferation \[[@pone.0238509.ref039]\]. It has been also shown that suppressing the increased expression of inflammation-related factors such as TNF is considered to potentially suppress the migration of macrophages into tumor tissues and regulate inflammatory changes in the tumor environments, respectively \[[@pone.0238509.ref040]\]. In this study, we detected *Dendrobium* compound-induced TNF expression in monocytes treated with 20 μM of gigantol (**\#3**) or cypripedin (**\#4**), suggesting potentially inflammatory effects of these compounds at high concentration. Whereas 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl (**\#1**), chrysotoxine (**\#2**) and moscatilin (**\#5**) did not show obvious inflammatory effects on monocytes *in vitro*, only the novel compound **\#1** has shown promising immune modulatory effects in a dose-dependent manner. However, in a long-term LPS-stimulation, only the 10 μM of the compound **\#1** could downmodulate the LPS-induced TNF expression in all monocyte subsets, whereas the concentration of 20 μM induced TNF expression of unstimulated cells, suggesting dose- and treatment-duration-dependent immune modulatory effects and/or inflammatory effects of this compound.

Interleukin-6 (IL-6) is a cytokine with pleiotropic function, which are involved in host defense. In acute infection and/or tissue injury, monocytes/macrophages promptly produce IL-6 and contribute to removal of infectious agents and regeneration of damaged tissue through activation of immune, hematological, and acute-phase responses \[[@pone.0238509.ref041]\]. However, a dysregulation of IL-6 production and/or persistently increased IL-6 expression plays a pathological role in the development of various inflammatory diseases and cancers, thus IL-6 is a double-edged sword for the host \[[@pone.0238509.ref041]\]. Thus, the proper IL-6 expression is very important for host defense. In this study, although we did observe the reduction of the LPS-induced IL-6 production in monocytes, that were short-term treated with the compound **\#1**, we found strongly increased production of IL-6 in long-term treated monocytes ([Fig 5](#pone.0238509.g005){ref-type="fig"}). However, since we detected a decrease in LPS-induced TNF-expression under the same conditions, an increased IL-6 expression observed in this study may refer to increased monocyte activity against LPS-induced inflammation.

Conclusions {#sec015}
===========

In summary, we demonstrate herein immune modulatory effects of the new compound 4,5-dihydroxy-3,3′,4′-trimethoxybibenzyl on different monocyte subsets *ex vivo*, which can potentially be developed as *in vivo* immune modulatory drug in a broad spectrum of inflammation-driven diseases besides lung carcinomas. However, since *Dendrobium lindleyi* is widely distributed, using this orchid for drug development may have a risk of habitat destruction, over-collection and commercially trade due to low natural regeneration rates. Moreover, *Dendrobium* plants are listed on Appendix II (*D*. *cruentum* is the only species listed on Appendix I) of Convention on International Trade in Endangered Species of Wild Fauna and Flora \[[@pone.0238509.ref042]\], which monitors, regulates or bans the trade to ensure species survival \[[@pone.0238509.ref043]\]. Therefore, in parallel to drug development, an establishment and improvement of methodologies/techniques for seedling propagation and artificial cultivation technology such as tissue culture and artificial-sheltered cultivation \[[@pone.0238509.ref044]--[@pone.0238509.ref047]\] are required to ensure sustainable development and future marketing.

The authors are grateful to Christian Böttcher for providing helpful technical support with the generation of PBMCs.
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Reviewer \#1:

The manuscript of Pichayatri Khoonrit et al. describes the potential immunomodulatory properties of compounds isolated from Thai orchid Dendrobium lindleyi. The manuscript is significant as the presented study determine the first report of chemical constituents and biological activities of gigantol, cypripedin, chrysotoxine, moscatilin and newly discovered ,4,5-dihydroxy-3,3',4'-trimethoxybibenzyl derivative, isolated form the orchid Dendrobium lindleyi. In order to assess the immune modulatory activities of these compounds, the authors established an ex vivo culture model of primary human monocytes with low cell attachment, which allows to avoid the phenotypic and functional changes, such as an increased granularity and reduced transendothelial diapedesis function in monocytes. The results of the study revealed an increased frequencies of TNF- and IL-6-expressing monocytes after cells treatment with two of five compounds (gigantol and cypripedin), whereas chrysotoxine and moscatilin did not upregulated the expression of these cytokines in monocytes. Moreover, the authors showed that the newly isolated 4,5-dihydroxy-3,3˘,4˘-trimethoxybibenzyl derivative downregulated lipopolysaccharide-induced cytokine production of primary human monocytes and concluded that these results suggest an anti-inflammatory activity of this agent. The study is preliminary, however it provides novel information regarding the immunomodulatory effects of orchid-derived compounds, which were previously described as promising inhibitory agents of lung cancer growth and metastasis. The flow cytometry experiments are well-planned and the results are clearly presented.

Response:

We thank the reviewer for this very supportive comment.

However, I have some suggestions to the authors.

Concern \#1: The manuscript is well written, however some typographical and grammatical errors have appeared:

\- Page 4, line 2 -- '...which have been already been shown..', the second 'been' has to be removed.

\- Page 6, Line 21 - The sentence: „To do so, the isolated monocytes were first incubated in the presence of the compound \#1 for two hours followed by overnight LPS-stimulation in a presence of monensin (5 μg/ml) longer incubation times with the Dendrobium compounds" has to be corrected.

Response:

We sincerely thank the reviewer for thorough proof-reading and apologize for such a mistake. We have corrected these sentences as suggested.

Concern \#2: Page 5, line 4 -- I recommend to add two abbreviations of monocyte chemoattractant protein-1 (MCP-1/CCL2), since on figure 2, both of these shortcuts appeared (Fig. 2E -- CCL2; Fig. 2F -- MCP-1).

Response:

We thank the reviewer for this suggestion and have revised the text accordingly.

Concern \#3: In my opinion the figures 4C and 4D can be deleted since they display the same data as figures 4A and 4B.

Response:

We thank the reviewer for the comment. However, although they are a kind of redundancy, we think that the Fig 4C and 4D would serve as a good summary of Fig 4A and 4B, which would help readers to directly compare all conditions together. Therefore, we would like to keep the Fig. 4C and 4D.

Concern \#4: The Introduction section is ended with the sentence :'Interestingly, the new 4,5-dihydroxy-3,3',4'-trimethoxybibenzyl derivative alleviated lipopolysaccharide (LPS)-induced cytokine production of primary human monocytes, suggesting anti-inflammatory activity.' This summary is too far-reaching, therefore the information about further validation of the results has to be added (examples: However, these results need to be further validated in in vivo studies or further studies elucidating the molecular pathway are needed).

Response:

We agree with the reviewer that the sentence is possibly overstated. We have now reworded it as suggested.

Concern \#5: The results represent well designed flow cytometry study, however, the measured parameters are limited. In the future, it would have been further interesting if the effect of examined compounds, most of all, the new 4,5-dihydroxy-3,3˘,4˘-trimethoxybibenzyl derivative, will be checked on other parameters, like the production of molecules responsible for killing of pathogens (H2O2, NO) or the phagocytic ability of human monocytes.

Response:

We thank the reviewer for the suggestion. As it has been shown in the results section, different monocyte subsets have different potential of producing inflammatory cytokine/mediators, and displayed different responses to the tested compounds. It is known that different monocyte subsets possess unique phenotypes and functions (Cros et al. Immunity 2010). Thus, as also suggested by the reviewer, it needs to be precisely investigated how each monocyte subset responses to the treatment with the target compound. We plan to apply high dimensional cell profiling technology such as mass cytometry (assessment of up to 40 markers on one cell: Böttcher et al. Nat. Neurosci. 2019, and Sankowski\*, Böttcher\* et al. Nat. Neurosci. 2019), in order to achieve comprehensive information on drug-related phenotypic and functional changes, as well as cell signaling.

Concern \#6: The authors order is different in "Orders of Authors" section and in the manuscript text.

Response:

We apologize for the mistake. The author order should be as addressed in the manuscript.

Reviewer \#2:

The fact is that macrophages, an important population of cells, are involved primarily in defense against infectious disease and play a central role in maintaining all tissues in a healthy state. On the other hand, macrophages also have a multifaceted role in diseases such as cancer, Alzheimer disease, multiple sclerosis and type 1 diabetes... I think that the topic is interesting, the introduction is sufficient to understand the issue, but that the results within the text should be confirmed by statistics. The methods are well described as well as the presentation of the obtained results (Figures). However, I would like to see more data confirming the macrophage function after treatment with isolated components from a Thai orchid Dendrobium lindleyi Steud such as phagocytosis ability, confirmation of cytotoxicity in co-culture with tumor cells and measurement of NO and H2O2 levels as well as confirmation of anti-inflammatory effect of components through COX-2 inhibition and LOX activities. I believe that confirming the functional ability of macrophages could better link the importance of secretion of individual cytokines with respect to cytokine pleiotropy and redundancy and better and more clearly confirm their immunomodulatory role in health or disease. By confirming the functional capacity of macrophages, the whole research would confirm the greater possibility of application of these components and better justify the mentioned project in plant protection. Such a presentation gives only possible assumptions without confirming the true immunomodulatory role of the isolated components.

Response:

We appreciate the reviewer's comments and also agree that the conclusion of the study might give an impression of being overstated, as it has been also mentioned by the reviewer \#1. We have therefore reworded the main text, where it is required, in order to be less speculative. Furthermore, we have revised the main text to make it more clear regarding the aim and future perspectives of the project.

As we have addressed in the introduction and the results, in this study we aimed to evaluate immune modulatory effects of the five compounds on circulating monocytes ex vivo. These cells possess different phenotypes and functions, compared to tissue-resident (or tumor-associated/infiltrating) macrophages. Most of available cell culture models provide systems for study monocyte-derived cells, which resemble tissue macrophage phenotypes and functions rather than those of circulating monocytes. Therefore, we first validated the use of low-attachment culture system to mimic circulating nature of monocytes, and thus avoid them to become adherent macrophage. Using this low-attachment culture system, we are able to detect all three subsets of circulating monocytes, which are CD14+CD16-, CD14+CD16+ and CD16+CD14- populations, thus are able to model all monocyte subsets ex vivo. We then further demonstrated immune modulatory effects of the tested compounds on different monocyte subsets. It remains however to further investigate:

1\) which monocyte subsets (CD14+ or CD14-) are the ones infiltrating to the tissue (or tumor), and further differentiate to tissue-macrophage (or tumor-associated macrophage)

2\) whether monocyte-derived macrophages serve as a direct effector at the site of cancer/diseases, and thus potentially provide therapeutic benefit. Or the compound-related therapeutic effects would rather be provided from circulating monocytes directly in the peripheral blood circulation.

3\) whether the observed immune modulatory effects could be maintained after monocyte differentiation to tissue (or tumor-associated) macrophage

Furthermore, the immune modulatory effects of the compounds may also provide beneficial effects in a broader spectrum of inflammation-driven diseases such as Chron's disease (CD), besides lung cancer. In our previous studies (Ziegler\*, Böttcher\* et al. Nat. Commun. 2019; Böttcher et al. Sci. Rep. 2019), we have demonstrated phenotypic and functional changes of circulating myeloid cells including monocytes in CD, suggesting their important roles in this pathology. Currently, it is our focus to further investigate (using our low-attachment culture system) whether the compounds (especially the new compound, \#1) would also provide therapeutic benefits on circulating monocytes obtained from the peripheral blood of patients with CD (ongoing project).

In addition, as shown in Fig. 2, different monocyte subsets have different potential of producing inflammatory cytokine/mediators. And it is known that different monocyte subsets possess different migratory potential to the tissue (or site of tumor). Thus, it needs to be further investigated, after exposing to the compounds, which monocyte population would provide more therapeutic benefits (immune modulatory effects vs activation-associated (on-site function)) function such as phagocytosis, cytotoxicity. To prove this assumption, we plan to analyse each monocyte subset after a treatment with the desired compound using single-cell sorting and analysis technology (as have been published by us recently, Böttcher et al. Nat. Neurosci. 2019; Sankowski\*, Böttcher\* et al. Nat. Neurosci. 2019), as well as using microfluidic cell culture system to tract each cell population. Together, we would need to gain more information regarding potential cell signaling pathway, which may be different from those results from cell line studies, in order to target the right pathway.

Finally, as we have written in discussion: "....Our findings suggest an importance and/or feasibility of using ex vivo studied models of different primary human (immune) cells to estimate the therapeutic potential and/or any potential adverse effects of purified natural products, which will further facilitate the adjustment of developmental potential of each isolated compound in diseases....", we are confident that this study will encourage the colleagues, whose researches focus on ex vivo (or in vitro) therapeutic screening of natural products, to apply such a model on primary human cells.

Second, minor problems, there are some mistakes about editorial handling, e.g. % must be written close the number. Please harmonize the way of writing degree C. SI units should be used... (e.g. μg/ml should be μg/mL). Please separate the SI unit from the number. In vitro and in vivo should be written in italic\...\... . Statistical value P should be written in italic and with a capital letter. Abbreviations must be explained the first time they are used, both in the Abstract and again in the main text.

Response:

We thank the reviewer for thoroughly reading our manuscript. In the revised manuscript, we have improved the main text as suggested.
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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Reviewer \#2: Yes
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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